Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.

Russick J, Delignat S, Milanov P, Christophe O, Boros G, Denis CV, Lenting PJ, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Jul 9. pii: haematol.2018.210583. doi: 10.3324/haematol.2018.210583. [Epub ahead of print]

2.

The nitrone spin trap 5,5‑dimethyl‑1‑pyrroline N‑oxide binds to toll-like receptor-2-TIR-BB-loop domain and dampens downstream inflammatory signaling.

Muñoz MD, Gutierrez LJ, Delignat S, Russick J, Gomez Mejiba SE, Lacroix-Desmazes S, Enriz RD, Ramirez DC.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1152-1159. doi: 10.1016/j.bbadis.2019.01.005. Epub 2019 Jan 23.

PMID:
30684639
3.

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A.

Delignat S, Russick J, Gangadharan B, Rayes J, Ing M, Voorberg J, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 May;104(5):1046-1054. doi: 10.3324/haematol.2018.200279. Epub 2018 Dec 13.

4.

Inhibitor Formation in Congenital Hemophilia A: an Immunological Perspective.

Delignat S, Rayes J, Russick J, Kaveri SV, Lacroix-Desmazes S; ABIRISK consortium.

Semin Thromb Hemost. 2018 Sep;44(6):517-530. doi: 10.1055/s-0038-1657777. Epub 2018 Jun 4. Review.

PMID:
29864775
5.

Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.

Delignat S, Peyron I, El Ghazaly M, V Kaveri S, Rohde J, Mueller F, Lacroix-Desmazes S.

Cell Immunol. 2018 Sep;331:22-29. doi: 10.1016/j.cellimm.2018.05.002. Epub 2018 May 5.

PMID:
29751951
6.

Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies.

Slatter DA, Percy CL, Allen-Redpath K, Gajsiewicz JM, Brooks NJ, Clayton A, Tyrrell VJ, Rosas M, Lauder SN, Watson A, Dul M, Garcia-Diaz Y, Aldrovandi M, Heurich M, Hall J, Morrissey JH, Lacroix-Desmazes S, Delignat S, Jenkins PV, Collins PW, O'Donnell VB.

JCI Insight. 2018 Mar 22;3(6). pii: 98459. doi: 10.1172/jci.insight.98459.

7.

Absence of a neutralizing antibody response to humanized cobra venom factor in mice.

Ing M, Hew BE, Fritzinger DC, Delignat S, Lacroix-Desmazes S, Vogel CW, Rayes J.

Mol Immunol. 2018 May;97:1-7. doi: 10.1016/j.molimm.2018.02.018. Epub 2018 Mar 8.

PMID:
29525557
8.

Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.

Peyron I, Dimitrov JD, Delignat S, Gangadharan B, Srivastava A, Kaveri SV, Lacroix-Desmazes S.

Cell Immunol. 2018 Mar;325:64-68. doi: 10.1016/j.cellimm.2018.01.008. Epub 2018 Jan 31.

PMID:
29395036
9.

Complement C3 is a novel modulator of the anti-factor VIII immune response.

Rayes J, Ing M, Delignat S, Peyron I, Gilardin L, Vogel CW, Fritzinger DC, Frémeaux-Bacchi V, Kaveri SV, Roumenina LT, Lacroix-Desmazes S.

Haematologica. 2018 Feb;103(2):351-360. doi: 10.3324/haematol.2017.165720. Epub 2017 Nov 16.

10.

The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope.

Gilardin L, Delignat S, Peyron I, Ing M, Lone YC, Gangadharan B, Michard B, Kherabi Y, Sharma M, Pashov A, Latouche JB, Hamieh M, Toutirais O, Loiseau P, Galicier L, Veyradier A, Kaveri S, Maillère B, Coppo P, Lacroix-Desmazes S.

Haematologica. 2017 Nov;102(11):1833-1841. doi: 10.3324/haematol.2015.136671. Epub 2017 Jul 27.

11.

The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.

Gangadharan B, Ing M, Delignat S, Peyron I, Teyssandier M, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2017 Feb;102(2):271-281. doi: 10.3324/haematol.2016.148502. Epub 2016 Oct 6.

12.

Immunogenicity of long-lasting recombinant factor VIII products.

Ing M, Gupta N, Teyssandier M, Maillère B, Pallardy M, Delignat S, Lacroix-Desmazes S; ABIRISK consortium.

Cell Immunol. 2016 Mar;301:40-8. doi: 10.1016/j.cellimm.2015.12.006. Epub 2015 Dec 19. Review.

PMID:
26723503
13.

Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance.

Gupta N, Culina S, Meslier Y, Dimitrov J, Arnoult C, Delignat S, Gangadharan B, Lecerf M, Justesen S, Gouilleux-Gruart V, Salomon BL, Scott DW, Kaveri SV, Mallone R, Lacroix-Desmazes S.

Sci Transl Med. 2015 Feb 18;7(275):275ra21. doi: 10.1126/scitranslmed.aaa1957.

PMID:
25696000
14.

Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice.

Peyron I, Dimitrov JD, Delignat S, Gangadharan B, Planchais C, Kaveri SV, Lacroix-Desmazes S.

Haemophilia. 2015 Jan;21(1):e94-8. doi: 10.1111/hae.12579. Epub 2014 Dec 4. No abstract available.

PMID:
25471131
15.

Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A.

Gangadharan B, Delignat S, Ollivier V, Gupta N, Mackman N, Kaveri SV, Lacroix-Desmazes S.

J Thromb Haemost. 2014 Dec;12(12):2065-9. doi: 10.1111/jth.12740. Epub 2014 Oct 25.

16.

Predictive immunogenicity of Refacto AF.

Delignat S, Repessé Y, Gilardin L, Dimitrov JD, Lone YC, Kaveri SV, Lacroix-Desmazes S.

Haemophilia. 2014 Jul;20(4):486-92. doi: 10.1111/hae.12348. Epub 2013 Dec 30.

PMID:
24372710
17.

Thermodynamic analysis of the interaction of factor VIII with von Willebrand factor.

Dimitrov JD, Christophe OD, Kang J, Repessé Y, Delignat S, Kaveri SV, Lacroix-Desmazes S.

Biochemistry. 2012 May 22;51(20):4108-16. doi: 10.1021/bi300232d. Epub 2012 May 14.

PMID:
22559004
18.

Heme binds to factor VIII and inhibits its interaction with activated factor IX.

Repessé Y, Dimitrov JD, Peyron I, Farrokhi Moshai E, Kiger L, Dasgupta S, Delignat S, Marden MC, Kaveri SV, Lacroix-Desmazes S.

J Thromb Haemost. 2012 Jun;10(6):1062-71. doi: 10.1111/j.1538-7836.2012.04724.x.

19.

Activation state of platelets in experimental severe hemophilia A.

Teyssandier M, Delignat S, Rayes J, Bryckaert M, Jandrot-Perrus M, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2012 Jul;97(7):1115-6. doi: 10.3324/haematol.2012.065235. Epub 2012 Mar 14. No abstract available.

20.

Mannose-sensitive receptors mediate the uptake of factor VIII therapeutics by human dendritic cells.

Repessé Y, Dasgupta S, Navarrete AM, Delignat S, Kaveri SV, Lacroix-Desmazes S.

J Allergy Clin Immunol. 2012 Apr;129(4):1172-3; author reply 1174-5. doi: 10.1016/j.jaci.2012.01.048. Epub 2012 Feb 14. No abstract available.

PMID:
22336079
21.

Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A.

Delignat S, Repessé Y, Navarrete AM, Meslier Y, Gupta N, Christophe OD, Kaveri SV, Lacroix-Desmazes S.

Haemophilia. 2012 Mar;18(2):248-54. doi: 10.1111/j.1365-2516.2011.02679.x. Epub 2011 Nov 2.

PMID:
22044692
22.

Enhancement of the affinity of glucocorticoid receptors as a mechanism underlying the steroid-sparing effect of intravenous immunoglobulin.

Pashov A, Delignat S, Bayry J, Kaveri SV.

J Rheumatol. 2011 Oct;38(10):2275. doi: 10.3899/jrheum.110087. No abstract available.

PMID:
21965701
23.

CD4+CD25+ regulatory T cell-mediated changes in the expression of endocytic receptors and endocytosis process of human dendritic cells.

Navarrete AM, Delignat S, Teillaud JL, Kaveri SV, Lacroix-Desmazes S, Bayry J.

Vaccine. 2011 Mar 24;29(15):2649-52. doi: 10.1016/j.vaccine.2011.01.095. Epub 2011 Feb 23.

PMID:
21316501
24.

Bortezomib delays the onset of factor VIII inhibitors in experimental hemophilia A, but fails to eliminate established anti-factor VIII IgG-producing cells.

Meslier Y, André S, Dimitrov JD, Delignat S, Bayry J, Kaveri SV, Lacroix-Desmazes S.

J Thromb Haemost. 2011 Apr;9(4):719-28. doi: 10.1111/j.1538-7836.2011.04200.x.

25.

Endocytic receptor for pro-coagulant factor VIII: relevance to inhibitor formation.

Navarrete AM, Dasgupta S, Teyssandier M, Repesse Y, Delignat S, André S, Bayry J, Kaveri SV, Lacroix-Desmazes S.

Thromb Haemost. 2010 Dec;104(6):1093-8. doi: 10.1160/TH10-05-0294. Epub 2010 Sep 30. Review.

PMID:
20886186
26.

Induction of heme oxygenase-1 in factor VIII-deficient mice reduces the immune response to therapeutic factor VIII.

Dimitrov JD, Dasgupta S, Navarrete AM, Delignat S, Repesse Y, Meslier Y, Planchais C, Teyssandier M, Motterlini R, Bayry J, Kaveri SV, Lacroix-Desmazes S.

Blood. 2010 Apr 1;115(13):2682-5. doi: 10.1182/blood-2009-04-216408. Epub 2009 Nov 4.

27.

CD4+CD25+ regulatory T cells modulate human dendritic cell chemokines via multiple mechanisms: comment on the article by Kolar et al.

Navarrete AM, Meslier Y, Teyssandier M, André S, Delignat S, Triebel F, Kaveri SV, Lacroix-Desmazes S, Bayry J.

Arthritis Rheum. 2009 Sep;60(9):2848-9; author reply 2849-51. doi: 10.1002/art.24784. No abstract available.

28.

Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A.

Navarrete A, Dasgupta S, Delignat S, Caligiuri G, Christophe OD, Bayry J, Nicoletti A, Kaveri SV, Lacroix-Desmazes S.

J Thromb Haemost. 2009 Nov;7(11):1816-23. doi: 10.1111/j.1538-7836.2009.03571.x. Epub 2009 Aug 11.

29.

Antiangiogenic properties of viscum album extracts are associated with endothelial cytotoxicity.

Elluru SR, Duong Van Huyen JP, Delignat S, Prost F, Heudes D, Kazatchkine MD, Friboulet A, Kaveri SV.

Anticancer Res. 2009 Aug;29(8):2945-50.

30.

Modulation of human dendritic cell maturation and function by natural IgG antibodies.

Elluru SR, Vani J, Delignat S, Bloch MF, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV, Bayry J.

Autoimmun Rev. 2008 Jun;7(6):487-90. doi: 10.1016/j.autrev.2008.04.014. Epub 2008 May 7. Review.

PMID:
18558367
31.

Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer.

Elluru SR, Duong van Huyen JP, Delignat S, Kazatchkine MD, Friboulet A, Kaveri SV, Bayry J.

BMC Cancer. 2008 Jun 4;8:161. doi: 10.1186/1471-2407-8-161.

32.

Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation.

Dasgupta S, Navarrete AM, André S, Wootla B, Delignat S, Repessé Y, Bayry J, Nicoletti A, Saenko EL, d'Oiron R, Jacquemin M, Saint-Remy JM, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2008 Jan;93(1):83-9. doi: 10.3324/haematol.11535.

33.

Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.

Delignat S, Dasgupta S, André S, Navarrete AM, Kaveri SV, Bayry J, André MH, Chtourou S, Tellier Z, Lacroix-Desmazes S.

Haematologica. 2007 Oct;92(10):1423-6.

34.

Expansion of CD4+CD25+ regulatory T cells by intravenous immunoglobulin: a critical factor in controlling experimental autoimmune encephalomyelitis.

Ephrem A, Chamat S, Miquel C, Fisson S, Mouthon L, Caligiuri G, Delignat S, Elluru S, Bayry J, Lacroix-Desmazes S, Cohen JL, Salomon BL, Kazatchkine MD, Kaveri SV, Misra N.

Blood. 2008 Jan 15;111(2):715-22. Epub 2007 Oct 11.

35.

Intravenous immunoglobulins in autoimmune and inflammatory diseases: a mechanistic perspective.

Sibéril S, Elluru S, Graff-Dubois S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayry J, Kaveri SV.

Ann N Y Acad Sci. 2007 Sep;1110:497-506. Erratum in: Ann N Y Acad Sci. 2014 Nov;1330(1):121. Ann N Y Acad Sci. Bayary, Jagadeesh [corrected to Bayry, Jagadeesh].

PMID:
17911465
36.

Intravenous immunoglobulin in autoimmune and inflammatory diseases: more than mere transfer of antibodies.

Sibéril S, Elluru S, Negi VS, Ephrem A, Misra N, Delignat S, Bayary J, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV.

Transfus Apher Sci. 2007 Aug;37(1):103-7. Epub 2007 Aug 31. Review.

PMID:
17765663
37.

Phosphorylcholine-targeting immunization reduces atherosclerosis.

Caligiuri G, Khallou-Laschet J, Vandaele M, Gaston AT, Delignat S, Mandet C, Kohler HV, Kaveri SV, Nicoletti A.

J Am Coll Cardiol. 2007 Aug 7;50(6):540-6. Epub 2007 Jul 23.

38.

A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes.

Dasgupta S, Navarrete AM, Bayry J, Delignat S, Wootla B, André S, Christophe O, Nascimbeni M, Jacquemin M, Martinez-Pomares L, Geijtenbeek TB, Moris A, Saint-Remy JM, Kazatchkine MD, Kaveri SV, Lacroix-Desmazes S.

Proc Natl Acad Sci U S A. 2007 May 22;104(21):8965-70. Epub 2007 May 14.

39.

[Use of intravenous polyclonal immunoglobulins in autoimmune and inflammatory disorders].

Graff-Dubois S, Sibéril S, Elluru S, Negi VS, Delignat S, Mouthon L, Lacroix-Desmazes S, Kazatchkine MD, Bayary J, Kaveri SV.

Transfus Clin Biol. 2007 May;14(1):63-8. Epub 2007 May 10. Review. French.

PMID:
17498995
40.

Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.

Dasgupta S, Navarrete AM, Delignat S, Wootla B, Andre S, Nagaraja V, Lacroix-Desmazes S, Kaveri SV.

Immunol Lett. 2007 May 15;110(1):23-8. Epub 2007 Apr 13. Review.

PMID:
17467813
41.

VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors.

Dasgupta S, Repessé Y, Bayry J, Navarrete AM, Wootla B, Delignat S, Irinopoulou T, Kamaté C, Saint-Remy JM, Jacquemin M, Lenting PJ, Borel-Derlon A, Kaveri SV, Lacroix-Desmazes S.

Blood. 2007 Jan 15;109(2):610-2. Epub 2006 Sep 19.

42.

Comparative study of the anti-inflammatory effect of two intravenous immunoglobulin preparations manufactured by different processes.

Elluru S, Duong Van Huyen JP, Prost F, Delignat S, Bayry J, Ephrem A, Siberil S, Misra N, Lacroix-Desmzes S, Kazatchkine MD, Kaveri SV.

Immunol Lett. 2006 Sep 15;107(1):58-62. Epub 2006 Aug 22. Erratum in: Immunol Lett. 2006 Nov 15;107(2):182.

PMID:
16952403
43.

Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador.

Elluru S, Duong Van Huyen JP, Delignat S, Prost F, Bayry J, Kazatchkine MD, Kaveri SV.

Arzneimittelforschung. 2006 Jun;56(6A):461-6. Review.

PMID:
16927527
44.

Direct and indirect effects of alloantibodies link neointimal and medial remodeling in graft arteriosclerosis.

Thaunat O, Louedec L, Dai J, Bellier F, Groyer E, Delignat S, Gaston AT, Caligiuri G, Joly E, Plissonnier D, Michel JB, Nicoletti A.

Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2359-65. Epub 2006 Aug 17.

PMID:
16917106
45.

Catalytic IgG from patients with hemophilia A inactivate therapeutic factor VIII.

Lacroix-Desmazes S, Wootla B, Dasgupta S, Delignat S, Bayry J, Reinbolt J, Hoebeke J, Saenko E, Kazatchkine MD, Friboulet A, Christophe O, Nagaraja V, Kaveri SV.

J Immunol. 2006 Jul 15;177(2):1355-63.

46.

Intravenous immunoglobulin in autoimmune disorders: an insight into the immunoregulatory mechanisms.

Bayry J, Dasgupta S, Misra N, Ephrem A, Duong Van Huyen JP, Delignat S, Hassan G, Caligiuri G, Nicoletti A, Lacroix-Desmazes S, Kazatchkine MD, Kaveri S.

Int Immunopharmacol. 2006 Apr;6(4):528-34. Epub 2005 Dec 9. Review. Erratum in: Int Immunopharmacol. 2013 Jun;16(2):342. Bayary, Jagadeesh [corrected to Bayry, Jagadeesh].

PMID:
16504915
47.

Pathophysiology of catalytic antibodies.

Lacroix-Desmazes S, Wootla B, Delignat S, Dasgupta S, Nagaraja V, Kazatchkine MD, Kaveri SV.

Immunol Lett. 2006 Feb 28;103(1):3-7. Epub 2005 Nov 2. Review.

PMID:
16427704
48.

Interleukin-12 is associated with the in vivo anti-tumor effect of mistletoe extracts in B16 mouse melanoma.

Duong Van Huyen JP, Delignat S, Bayry J, Kazatchkine MD, Bruneval P, Nicoletti A, Kaveri SV.

Cancer Lett. 2006 Nov 8;243(1):32-7. Epub 2006 Jan 18.

PMID:
16412563
49.

Intravenous immunoglobulin and dendritic cells.

Misra N, Bayry J, Dasgupta S, Ephrem A, Huyen JP, Delignat S, Hassan G, Caligiuri G, Nicoletti A, Lacroix-Desmazes S, Kazatchkine MD, Kaveri SV.

Clin Rev Allergy Immunol. 2005 Dec;29(3):201-5. Review. Erratum in: Clin Rev Allergy Immunol. 2015 Oct;49(2):262. Bayary, Jagadeesh [corrected to Bayry, Jagadeesh].

PMID:
16391394
50.

Immunomodulation of autoimmune and inflammatory diseases with intravenous immunoglobulin.

Ephrem A, Misra N, Hassan G, Dasgupta S, Delignat S, Duong Van Huyen JP, Chamat S, Prost F, Lacroix-Desmazes S, Kavery SV, Kazatchkine MD.

Clin Exp Med. 2005 Dec;5(4):135-40. Review.

PMID:
16362793

Supplemental Content

Loading ...
Support Center